We have demonstrated that the gibbon ape leukemia virus (GALV) enhancer AP-1 element and the simian virus 40 AP-1 enhancer element bind different factors in HeLa nuclear extracts. A 39-kilodalton HeLa nuclear protein and the c-fos protein bind to the GALV element. Antibodies to c-fos abolish binding to the GALV AP-1 site. In contrast, anti-c-fos immunoglobulin fails to inhibit formation of the simian virus 40-specific complex from extracts of HeLa cells. Thus, AP-1-binding complexes are subject to compositional variation at different binding sites.
It was previously shown that the gibbon ape leukemia virus (GALV) Seato strain enhancer element is active in several uninfected cell lines and that the sequence responsible for this activity resides within a 155-base-pair (bp) area of the U3 region of the long terminal repeat (13) . This region contains three tandem direct and perfect repeats of a 48-bp sequence (22) . Within each of these repeats, a 22-bp sequence binds a cellular factor; this sequence has enhancer activity in vivo (22) . The 22-bp enhancer region contains the consensus sequence TGAG/CTCA, which is found in the binding site for the transcription factor AP-1 (2, 17) .
Purified AP-1 consists of a group of polypeptides ranging in size from 40 to 60 kilodaltons (kDa), with a major polypeptide of 47 kDa (2, 18) ; however, it is not clear whether these are different forms of the same molecule or related polypeptides. A functional relationship between AP-1 and c-fos has been suggested in that c-fos is part of a complex binding at AP-1 sites in certain cell lines (8, 24) . Consistent with this, the 39-kDa protein in AP-1 preparations purified by oligonucleotide affinity chromatography is the same as p39, a 39-kDa protein previously shown to coprecipitate with antibodies to c-fos (23) . This p39 is identical with the c-jun gene product (1, 3, 4) . The cjun-c-fos complex from H9 cells has been shown to bind to the GALV enhancer element (8) .
Although it has been shown that the 39-kDa protein in these AP-1 preparations is functional, several lines of evidence indicate the existence of a larger AP-1 family of proteins binding to AP-1 consensus sequences. There is strong homology of the murine jun B cDNA clone with vand c-jun (20, 25) . In yeast cells, the simian virus 40 (SV40) AP-1 element is trans-activated by proteins distinct from GCN4, thus demonstrating that different factors can transactivate AP-1 sites under different conditions (12, 15) .
To study the possibility that various (possibly related) factors would bind different AP-1 sites, double-stranded oligonucleotides conforming exactly to the GALV enhancer and SV40 AP-1-binding sites (16, 17, 21, 22) were compared by using gel retardation and competition studies. We also identified directly from crude nuclear extracts Gel retardation. Gel retardation analysis was performed as described previously (10, 26, 27 After passing crude serum through the columns, the columns were washed first with 150 mM NaCl-50 mM Tris-NaCl (pH 7.4) and then with 2 M NaCl until the optical density at 280 nm was 0. Antibodies were diluted after a 15-min washing with 4 M MgCl2.
Western immunoblotting of GALV-specific complexes precipitated with immunobeads. Precipitation of the protein abcd efg hi j klm complexes with GALV DNA immobilized on immunobeads was performed by a variation of the method described above. HeLa extract (2.5 mg of total protein) was mixed with 10 pLg of poly(dI)-poly(dC), 0. 
RESULTS
The specific protein in HeLa cells that binds the GALV enhancer is distinct from the major protein which binds the SV40 AP-1 element. The 22-bp oligonucleotide that has GALV enhancer activity contains a segment homologous to , the SV40-binding material was found in the flowthrough from the column, whereas the GALV-binding factor was retained on the column (Fig. 2) . That the GALV factor rather than the SV40 factor is the major biological effector of GALV enhancer activity is suggested by the correlation of the relative abundance (or affinities for cognate sequences) of these proteins in various cell lines with the relative enhancer activities of the GALV and SV40 enhancers in the same cells (Fig. 3) . The SV40 protein, which binds the SV40 enhancer, is considerably more abundant in HeLa cells than the GALV factor, whereas a reciprocal relationship exists in MLA-144 cells, in which the GALV enhancer has higher activity (13, 22 B,* * * the binding site of the previously purified trans-acting factor AP-1 (2, 17, 18) . AP-1 preparations contain a major peptide of 44 to 47 kDa. To explore the relationship between the factor(s) that binds to the GALV enhancer and those that interact with the SV40 enhancer, reciprocal competition studies were performed with the GALV 22-bp oligonucleotide (corresponding to the enhancer sequence) and the previously identified SV40 AP-1-binding site (17) as probes; each of these probes generated a distinctive shift with HeLa nuclear extract. Inclusion of excess unlabeled homologous or heterologous competitor indicated that the protein responsible for the GALV-specific shift binds with greater affinity to the GALV probe than the protein which binds the SV40 AP-1 site does and, conversely, that a protein specific for the SV40 AP-1 site binds more tightly to its binding site than that of the GALV sequence (Fig. 1) (Fig. 3) . fos is part of the complex at the GALV AP-1 site in HeLa cells. Although we detected no specifically precipitated peptides other than this 39-kDa protein binding directly to the GALV enhancer sequence, other specifically bound proteins such as fos, which has previously been reported to interact 29kD with the GALV enhancer element (8) Lsynthetic oligonucleotides comHeLa cell nuclear extract was incubated with GALV prising a segment of the GALV-Seato enhancer which possesses enhancer activity (22) enhancer DNA immobilized on beads or with pUC19 DNA immobilized on beads as a control. After the binding reaction, DNA-protein complexes on the beads were washed, and then the bound protein was eluted with 0.2% SDS. The eluted proteins were separated by SDS-PAGE and were then transferred to a nitrocellulose filter. The filter was probed with anti-fos antibody. The GALV DNA precipitated a major immunoreactive protein of 55 kDa, the correct molecular weight for c-fos, and related proteins (9) (Fig. 4B, lane  1) . pUC19 DNA precipitated only a trace of fos-reactive material (Fig. 4B, lane 3) . The binding of the 55-kDa peptide to the immobilized GALV DNA could be eliminated by inclusion of GALV DNA as a competitor in the binding reaction (Fig. 4B, lane 2) . This result confirms the presence of c-fos and/orfos-related proteins that participate in specific GALV DNA-protein complexes.
Effect offos antibody on AP-1 complexes. The abundance of c-fos protein precipitated with GALV-specific DNA bound to immunobeads suggested that c-fos was part of the complex with the 39-kDa protein. Addition of anti-c-fos immunoglobulin to gel retardation reactions inhibited the formation of the GALV-specific complex (Fig. 5) . The SV40-specific complex, which is shown to be distinct from the GALV complex by both reciprocal competition and chromatography, is not affected by addition of this same antibody. This argues against the SV40-specific complex containing c-fos and confirms that, in contrast, the GALV enhancer specifically binds c-fos in HeLa cells.
DISCUSSION
We have demonstrated that a protein of 39 kDa from HeLa cells is bound by the 48-bp repeated element of the GALV long terminal repeat shown previously to have enhancer activity. The binding of this protein can be eliminated by an oligonucleotide competitor corresponding to the previously footprinted region within the GALV element and which itself has enhancer function (22) but not by heterologous oligonucleotides. The 39-kDa protein is detected in HeLa cells that support GALV enhancer-activated transcription but not in Jurkat cells that do not trans-activate this enhancer; thus, the abundance and affinity of this protein are correlated with enhancer activity in these cells. The size of the bound protein is compatible with the known size of the product of the c-jun gene.
Reciprocal competition studies indicate that the GALV and SV40 AP-1 sites bind specific proteins and that the binding of these proteins is only reduced by cross-competition with a vast excess of competitor. The distinctive electrophoretic pattern of each of these oligonucleotide-protein complexes allowed us to separate the GALV factor and SV40 factor by ion exchange chromatography. The GALV complex, in addition to binding the 39-kDa protein, is also inhibited by antibodies to c-fos, whereas the SV40 complex is insensitive to addition of this antibody. This result suggests that c-fos is not part of the complex at the SV40 AP-1 site and dictates that, in the same cell line, proteins apart from c-jun and c-fos can interact with AP-1 sites.
These results have expanded the range of proteins that are capable of binding to the AP-1 site in addition to c-fos and c-jun. What determines specificity at AP-1 sites and allows discrimination between various DNA-protein complexes? It may be that we have to expand the consensus sequence such that flanking sequences confer additional specificity or that the variation known to exist within this consensus sequence allows for a limited number of proteins that are able to distinguish one site from another. Preliminary evidence suggests that the factors which bind the GALV and SV40 AP-1 sites can be different in various cell lines (data not shown). Modulation of the presence or abundance of factors which are available may determine the physiological or pathological activities of these sequences. Further purification of the factors from HeLa and MLA-144 cells should better our understanding of the combinatorial use of factors at AP-1 sites.
